NEW YORK, May 17, 2016 (GLOBE NEWSWIRE) -- Mid-Atlantic Bio Angels (MABA) announces today that Prevnos, Inc. (http://www.prevnos.com) was voted as “Best in Show” at MABA's 1st Pitch Life Science event, which took place at the Institute for Life Science Entrepreneurship in Union, NJ on May 5, 2016. Prevnos is a Union, NJ-based diagnostics company developing Hybrid Fusion FISH™ assays for diagnosis and treatment of certain cancers.
“We were honored to have been chosen as ‘Best in Show’ as it confirms that approach to our science and business are viable and investment-ready,” said Mohammed Harris, founder and CEO of Prevnos. “We are grateful for the opportunity to receive the feedback of the panel and look forward to applying it to the advancement of our business.”
1st Pitch Life Science (http://www.1stpitchlifescience.com) has been organized by MABA, a life science investor group, to encourage and educate aspiring life science entrepreneurs who know they may be too early to seek investment but want the opportunity to practice their pitch and to receive constructive criticism from experienced and knowledgeable professionals.
"Mr. Harris had intimate knowledge of the market being addressed and was able to articulate Prevnos' value proposition and competitive advantages in his presentation," said Anjan Aralihalli, a Member of Mid-Atlantic Bio Angels.
About Mid Atlantic Bio Angels
Mid Atlantic Bio Angels (http://bioangels.net) is a group of active angel investors, which meets in New York City monthly (except July and August) solely to hear from pre-screened early-stage life science companies. MABA members consist of individuals from Delaware to Massachusetts with significant expertise and experience in the biotechnology, pharmaceutical and healthcare industries, including former and current corporate executives, doctors and Ph.D. scientists with product development backgrounds, successful medical entrepreneurs and analyst/investors focused on life sciences. MABA's goal is to create an environment where the depth of investors' knowledge coupled with the pre-screening of presenting companies enhances the potential for meaningful investment.
Prevnos (www.prevnos.com) is a cancer diagnostics company for the early detection, active surveillance and diagnosis of cancer. As the inventor of the world’s first Hybrid Fusion FISH™ tests which utilize simple “colored dots” to detect cancer in suspension samples (blood, urine, saliva) and solid tumor biopsies (formalin-fixed paraffin-embedded tissues), Prevnos is advancing personalized diagnostics in cancer genetics for circulating tumor cells (CTCs) for targeted cell enrichment, early detection, and residual disease monitoring for precision medicine in oncology. Prevnos is actively involved with large pharmaceutical and clinical reference laboratories throughout the US for the development of companion diagnostics for targeted therapies.
CONTACT: Jules Abraham JQA Partners, Inc. email@example.com 917-885-7378
Source: Mid Atlantic Bio Angels